Huntington's Disease: Current and Future Therapeutic Prospects

Overview

Journal Mov Disord

Date 2018 May 9

PMID 29737569

Citations 11

Authors

Karl Kieburtz

Ralf Reilmann

C Warren Olanow

Affiliations

Soon will be listed here.

Abstract

Huntington's disease is a progressive neurodegenerative disorder for which therapies are woefully inadequate and do not prevent inevitable progression. Currently approved therapies are primarily aimed at treating chorea, but do not address the more clinically meaningful motor, behavioral, and cognitive features of the disease. However, there are a number of promising new therapies that are currently being studied in the laboratory, and in the clinic. This article will review the wide variety of therapies currently being tested, the advances in clinical trials and end points, and the many potentially relevant new targets. © 2018 International Parkinson and Movement Disorder Society.

Citing Articles

Systemic Rejuvenating Interventions: Perspectives on Neuroinflammation and Blood-Brain Barrier Integrity.

de Rezende V, de Aguiar da Costa M, Martins C, Mathias K, Goncalves C, Barichello T Neurochem Res. 2025; 50(2):112.

PMID: 40035979 DOI: 10.1007/s11064-025-04361-7.

The Efficacy and Safety of Pridopidine on Treatment of Patients with Huntington's Disease: A Systematic Review and Meta-Analysis.

Asla M, Nawar A, Abdelsalam A, Elsayed E, Rizk M, Hussein M Mov Disord Clin Pract. 2022; 9(1):20-30.

PMID: 35005061 PMC: 8721839. DOI: 10.1002/mdc3.13357.

The Emerging Role of Phosphodiesterases in Movement Disorders.

Erro R, Mencacci N, Bhatia K Mov Disord. 2021; 36(10):2225-2243.

PMID: 34155691 PMC: 8596847. DOI: 10.1002/mds.28686.

A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity.

Khaled H, Feng H, Hu X, Sun X, Zheng W, Li P Sci Rep. 2021; 11(1):6157.

PMID: 33731741 PMC: 7969751. DOI: 10.1038/s41598-021-85279-2.

Tolerability and psychological effects of a multimodal day-care rehabilitation program for persons with Huntington's disease.

Ringqvist K, Borg K, Moller M J Rehabil Med. 2020; 53(1):jrm00143.

PMID: 32989469 PMC: 8772368. DOI: 10.2340/16501977-2748.